Navigation Links
PLC Systems Reports Third Quarter 2009 Results; Announces Distribution Agreement for RenalGuard(R) in Brazil
Date:11/10/2009

FRANKLIN, Mass., Nov. 10 /PRNewswire-FirstCall/ -- PLC Systems Inc. (OTC Bulletin Board: PLCSF), a company focused on innovative cardiac and vascular medical device-based technologies, today reported financial results for the three and nine month periods ended September 30, 2009.

Third quarter 2009 total revenues were $1,023,000, down from $1,598,000 in the third quarter of 2008. The net loss for the third quarter of 2009 was $358,000, or $0.01 per diluted share, compared to a net loss of $285,000, or $0.01 per diluted share, in the third quarter of 2008.

Mark R. Tauscher, president and chief executive officer of PLC Systems Inc., stated, "This past quarter saw the first public release of very positive preliminary data from the clinical trial of our RenalGuard System(TM) in Italy. The data was presented at two significant medical conferences: in Spain in late August and a month later in the U.S., providing us with important opportunities to respond to growing interest from practitioners and potential distributors about RenalGuard®. In the initial data, only 4.6% of patients treated with RenalGuard in the trial acquired Contrast- Induced Nephropathy (CIN) whereas 14.9% of the patients in the control group were determined to have acquired CIN, thus demonstrating an advantage to using RenalGuard with the ever-growing segment of at-risk patients undergoing imaging procedures."

He added, "We have always believed that positive data from the Italian clinical study would drive additional distributor agreements, and our announcement today of a distribution agreement in Brazil, a very large potential market for RenalGuard, confirms our confidence. Based upon the number of discussions in which we are now engaged for potential distribution around the world, we are very pleased with the results of our participation in these conferences As the number of distributors has increased, with RenalGuard now on the market in Italy, Spain, Bangladesh and Pakistan, we also hope to use the heightened interest to generate stronger sales."

Separately, PLC announced today that that it has entered into a five year exclusive agreement with DISCOMED Comercio de Produtos Hospitalares Ltda., of Porto Alegre, Brazil, for distribution of its RenalGuard System(TM) in Brazil. DISCOMED is an established distributor of medical technology and devices in Brazil. DISCOMED is applying for an import license through ANVISA, the Brazilian registration authority, and expects approval in approximately 9 months.

PLC shipped 275 single use sets associated with its RenalGuard System internationally during the third quarter of 2009, along with nine consoles, associated with its launch of RenalGuard in Italy and Spain. In comparison, the company shipped 50 RenalGuard sets and five consoles in the third quarter of 2008.

During the third quarter of 2009, 223 disposable TMR kits were shipped, consisting of 218 kits shipped to hospitals in the U.S. by Novadaq Technologies, PLC's U.S. TMR marketing and distribution partner, and five kits shipped internationally by PLC. In comparison, a total of 409 disposable TMR kits were shipped worldwide during the third quarter of 2008.

PLC recorded no new domestic or international laser sales during the third quarter of 2009. In the same quarter of 2008, PLC shipped three new CO2 Heart Lasers (HL2). PLC ended the third quarter of 2009 with 168 HL2 lasers located at heart centers throughout the U.S.

Nine Months Results

For the first nine months of 2009, total revenues were $3,810,000, compared to $4,076,000 in the same period of 2008. The net loss for the first nine months of 2009 was $1,023,000, or $0.03 per share, compared to a net loss of $1,718,000, or $0.06 per share, in the first nine months of 2008.

Conference Call

PLC Systems will host a conference call today, November 10, 2009, at 11:00 a.m. ET to discuss these matters. The call may be joined by dialing (800) 561-2718, or internationally, (617) 614-3525 at least ten minutes prior to the start of the call. The passcode is 31036960. A live webcast of the call will be accessible at the investor relations section of the Company's website at www.plcmed.com. An archived webcast of the conference call will be available beginning one hour after the completion of the call in the same location.

About PLC Systems Inc.

PLC Systems Inc. is a medical technology company specializing in innovative technologies for the cardiac and vascular markets. Headquartered in Franklin, Massachusetts, PLC pioneered the CO2 Heart Laser System, which cardiac surgeons use to perform CO2 transmyocardial revascularization (TMR) to alleviate symptoms of severe angina. PLC's newest product, RenalGuard, is approved for sale in the EU as a general fluid balancing device. Additional company information can be found at www.plcmed.com.

This press release contains "forward-looking" statements. For this purpose, any statements contained in this press release that relate to prospective events or developments are deemed to be forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "will" and similar expressions are intended to identify forward-looking statements. Our statements of our objectives are also forward-looking statements. While we may elect to update forward-looking statements in the future, we specifically disclaim any obligation to do so, even if our estimates change, and you should not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this press release. Actual results could differ materially from those indicated by such forward-looking statements as a result of a variety of important factors, including that we may not receive necessary regulatory approvals to market our RenalGuard product or that such approvals may be withdrawn, we may be unable to raise sufficient funds in the future to implement our business plan and/or commence our planned U.S. clinical trial for RenalGuard, the current clinical trials in Italy and the planned future U.S. clinical trial for RenalGuard may not be completed in a timely fashion, if at all, or, if these clinical trials are completed, they may not produce clinically significant or meaningful results, the RenalGuard product may not be commercially accepted, operational changes, competitive developments may affect the market for our products, regulatory approval requirements may affect the market for our products, and additional risk factors described in the "Forward Looking Statements" section of our Annual Report on Form 10-K for the year ended December 31, 2008, and our other SEC reports.

PLC Systems, PLC Medical Systems, PLC, CO2 Heart Laser, RenalGuard and RenalGuard System are trademarks of PLC Systems Inc.

Novadaq is a trademark of Novadaq Technologies, Inc.

    Contact:  Mary T. Conway
              Conway Communications
              617-244-9682
              mtconway@att.net
                                 PLC SYSTEMS INC.
                       CONSOLIDATED STATEMENTS OF OPERATIONS
                       (In thousands, except per share data)

                                         Three Months Ended  Nine Months Ended
                                            September 30,      September 30,
                                            2009    2008      2009      2008
                                            ----    ----      ----      ----
    Revenues:
      Product sales                         $701  $1,203    $2,824    $3,041
      Service fees                           322     395       986     1,035
                                             ---     ---       ---     -----
         Total revenues                    1,023   1,598     3,810     4,076
                                           -----   -----     -----     -----
    Cost of revenues:
      Product sales                          311     647     1,059     1,290
      Service fees                           189     182       516       517
                                             ---     ---       ---       ---
         Total cost of revenues              500     829     1,575     1,807
                                             ---     ---     -----     -----
    Gross profit                             523     769     2,235     2,269
                                             ---     ---     -----     -----
    Operating expenses:
      Selling, general and administrative    702     619     2,667     2,420
      Research and development               180     516       594     1,726
                                             ---     ---       ---     -----
         Total operating expenses            882   1,135     3,261     4,146
    Loss from operations                    (359)   (366)   (1,026)   (1,877)

    Other income, net                          1      11         3        89
                                              --      --        --        --
    Loss before income taxes                (358)   (355)   (1,023)   (1,788)
    Benefit from income taxes                  -     (70)        -       (70)
                                             ---    ----       ---      ----
    Net loss                               $(358)  $(285)  $(1,023)  $(1,718)
                                           =====   =====  ========  ========
    Basic and diluted loss per share      $(0.01) $(0.01)   $(0.03)   $(0.06)
    Average shares outstanding:
      Basic and diluted                   30,351  30,332    30,351    30,331



                               CONDENSED BALANCE SHEET

                                                   September 30, December 31,
                                                           2009         2008
                                                           ----         ----
    Cash and cash equivalents                            $3,252       $5,026
    Total current assets                                  5,648        7,562
    Total assets                                          5,924        7,913
    Total current liabilities                             2,941        3,364
    Shareholders' equity                                  2,302        3,191


SOURCE PLC Systems Inc.


'/>"/>
SOURCE PLC Systems Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. PLC Systems Announces Distribution Agreement for RenalGuard(R) in Brazil
2. China National Medicines Corporation Issues Milestone Purchase Order for 12,000 STA Systems
3. Varian Medical Systems Selected to Supply Major Project to Bring Advanced Radiotherapy Treatments to North of Portugal
4. Varian Medical Systems to Exhibit a Wide Selection of Flat Panel X-Ray Image Detectors and X-Ray Tubes at the CMEF Show in Chengdu, China
5. Delcath Systems, Inc. Completes Phase III Study Enrollment
6. Enhanced Food Safety and Systems Interoperability the Themes of Food Traceability Interoperability Summit 2010
7. Circle Medical Devices, Texcel Medical Merge to Form CIRTEC Medical Systems
8. Leading Trauma Surgeon Paints a Bleak Picture of U.S. Trauma System - Calls for Surgeons to Advocate for Systems Where Lacking
9. FDA Orders Postmarket Surveillance Studies on Certain Spinal Systems
10. Misonix, Inc. Announces the Sale of Sonora Medical Systems for $8 Million
11. Delcath Systems, Inc. Appoints Dr. Krishna Kandarpa its Executive Vice President R&D and Chief Medical Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... June 24, 2016  Global Blood Therapeutics, Inc. (GBT) ... developing novel therapeutics for the treatment of grievous ... the closing of its previously announced underwritten public ... the public offering price of $18.75 per share. ... offered by GBT. GBT estimates net proceeds from ...
(Date:6/24/2016)... , June 24, 2016 The Academy of ... recommendations that would allow biopharmaceutical companies to ... entities that make formulary and coverage decisions, a move ... of new medicines. The recommendations address restrictions ... appear on the drug label, a prohibition that hinders ...
(Date:6/24/2016)... 2016 According to a new ... Pen Needles, Safety Pen Needles), Needle Length (4mm, 5mm, ... Mode of Purchase (Retail, Non-Retail) - Trends & Global ... the market for the forecast period of 2016 to ... Billion by 2021 from USD 1.65 Billion in 2016, ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... June 26, 2016 , ... Many women ... diagnosed with endometriosis. These women need a treatment plan to not only alleviate ... that can help for preservation of fertility and ultimately achieving a pregnancy. The ...
(Date:6/25/2016)... ... June 25, 2016 , ... The temporary closing of Bruton Memorial Library on June ... , brings up a new, often overlooked aspect of head lice: the parasite’s ability to ... is not a common occurrence, but a necessary one in the event that lice have ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, ... and his M.D from the David Geffen School of Medicine at UCLA. He trained ... Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where ...
(Date:6/25/2016)... Montreal, Canada (PRWEB) , ... June 25, 2016 , ... ... the pursuit of success. In terms of the latter, setting the bar too high ... low, risk more than just slow progress toward their goal. , Research from ...
(Date:6/24/2016)... , ... June 24, 2016 , ... June 19, 2016 ... dangers associated with chronic pain and the benefits of holistic treatments, Serenity Recovery ... are suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a disorder ...
Breaking Medicine News(10 mins):